DBS

Switch Health develops Canada’s first at-home diagnostic Diabetes test

Retrieved on: 
Thursday, November 30, 2023
Patient, Purolator, Glucose, Interview, Risk, Death, STI, Kidney, Insulin, Diabetes Canada, Diabetes, HPV, Glycated hemoglobin, Hospital, Kidney disease, DBS, A1C, CSI: Vegas, Cell, Cardiovascular disease, Medical device

Switch Health's innovative at-home HbA1c test allows people with diabetes or those suspecting the condition to collect Dry Blood Spot (DBS) samples at home.

Key Points: 
  • Switch Health's innovative at-home HbA1c test allows people with diabetes or those suspecting the condition to collect Dry Blood Spot (DBS) samples at home.
  • To get started, users can visit the Switch Health website, select the HbA1c test kit, and complete an intake form, which determines medical necessity and public coverage of test processing (currently only for Ontario residents.)
  • According to Diabetes Canada , people living with diabetes face a higher risk of hospitalization due to cardiovascular disease and end-stage renal disease.
  • This marks Switch Health's latest at-home, self-collected test, following the introduction of at-home HPV and STI testing kits this fall.

Quectel launches SG520B series of 5G Sub-6GHz smart modules with powerful multimedia functionality

Retrieved on: 
Thursday, December 7, 2023
Consumer Electronics, IOT (Internet of Things), Apps, Applications, Technology, Mobile, Wireless, Networks, Qualcomm, CPE, Sale, IEEE, DBS, Internet of things, Android, NSA, Wi-Fi, Bluetooth, LGA, CSO, Multimedia, GNSS, System, MiFi, POS, MIMO, HP EliteBook, PDA, Temperature, Environment, LTE, Mobile phone

Quectel Wireless Solutions, a global IoT solutions provider, announces the new Quectel SG520B series of 5G Sub-6GHz, Wi-Fi 6E and Bluetooth smart modules.

Key Points: 
  • Quectel Wireless Solutions, a global IoT solutions provider, announces the new Quectel SG520B series of 5G Sub-6GHz, Wi-Fi 6E and Bluetooth smart modules.
  • View the full release here: https://www.businesswire.com/news/home/20231207674182/en/
    Quectel launches SG520B series of 5G Sub-6GHz smart modules with powerful multimedia functionality (Photo: Business Wire)
    Offering comprehensive cellular connectivity options including worldwide 2G, 3G, 4G and 5G coverage, with LTE Cat 15 and both 5G Release 16 standalone (SA) and 5G non-standalone (NSA), the modules offer 5G and LTE multiple input multiple output (MIMO) technology.
  • “The Quectel SG520B Series of 5G Sub-6GHz smart modules are powerful, versatile modules that are ideal for enabling rich device functionality alongside unparalleled connection performance across multiple cellular, Wi-Fi and Bluetooth options,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions.
  • For 5G NSA deployments, the modules will support 2.5Gbps downlink and 550Mbps uplink, again depending on which regional variant is selected.

Masdar Joins Forces with RWE in £11 billion Investment to Co-develop Massive 3GW Offshore Wind Projects in UK

Retrieved on: 
Friday, December 1, 2023
London Array, RWE, Coal, DBS, International Renewable Energy Agency, Dudgeon, UN, COP28, RWE AG, Investment, PJSC, Wind, Dogger Bank, Solar energy, Farm, Growth, Electricity, Temperature, Renewable energy, Drug, Masdar

The 3GW DBS projects bring together global clean energy pioneers Masdar and RWE, a leading renewable energy company headquartered in Germany.

Key Points: 
  • The 3GW DBS projects bring together global clean energy pioneers Masdar and RWE, a leading renewable energy company headquartered in Germany.
  • Today's investment in the 3GW DBS projects - almost five times as big as London Array - shows Masdar's steadfast expansion into the exciting offshore wind sector.
  • Masdar has also invested in the 30MW Hywind project, which was the world's first floating offshore wind farm, and the 402MW Dudgeon offshore wind farm.
  • RWE is already one of the leading companies in the field of renewable energy and offshore wind.

Masdar Joins Forces with RWE in £11 billion Investment to Co-develop Massive 3GW Offshore Wind Projects in UK

Retrieved on: 
Friday, December 1, 2023
London Array, RWE, Coal, DBS, International Renewable Energy Agency, Dudgeon, UN, COP28, RWE AG, Investment, PJSC, Wind, Dogger Bank, Solar energy, Farm, Growth, Electricity, Temperature, Renewable energy, Drug, Masdar

The 3GW DBS projects bring together global clean energy pioneers Masdar and RWE, a leading renewable energy company headquartered in Germany.

Key Points: 
  • The 3GW DBS projects bring together global clean energy pioneers Masdar and RWE, a leading renewable energy company headquartered in Germany.
  • Today's investment in the 3GW DBS projects - almost five times as big as London Array - shows Masdar's steadfast expansion into the exciting offshore wind sector.
  • Masdar has also invested in the 30MW Hywind project, which was the world's first floating offshore wind farm, and the 402MW Dudgeon offshore wind farm.
  • RWE is already one of the leading companies in the field of renewable energy and offshore wind.

Spear Bio, developer of the next-generation ultrasensitive immunodiagnostics and proteomics platform, completes raise of tens of millions of US dollars with oversubscribed Seed Prime

Retrieved on: 
Wednesday, November 29, 2023
Microfluidics, DBS, Immunity, Research, DNA, Conditional sentence, Proteomics, Investment, Protein, Reproductive success, Disease, CDH, Patient, Multimedia, Neurology, Laboratory, SPEAR, Harvard University, Infection, COVID-19, Workflow, Ultra, Biomarker, Real-time, Wyss Institute, ELISA, Partnership, CDH Investments, Pharmaceutical industry, Medical imaging, Hunting

The oversubscribed round was led by CDH Investments, with additional investments from earlier investors such as Maverick Ventures and YongHua Capital.

Key Points: 
  • The oversubscribed round was led by CDH Investments, with additional investments from earlier investors such as Maverick Ventures and YongHua Capital.
  • Spear Bio was co-founded in March 2021 as a spin-off from Harvard University's Wyss Institute by Professor Peng Yin and Dr. Feng Xuan.
  • The company is developing the next generation ultrasensitive immunodiagnostics and proteomics platform based on a breakthrough technology its founders developed and licensed from Harvard University: the Successive Proximity Extension Amplification Reaction, or SPEAR.
  • Spear Bio is now focused on bringing to market ultrasensitive immunoassays for areas such as neurology, immunology, and oncology.

EQS-News: Francotyp-Postalia achieves earnings at the previous year's level in the first nine months of 2023

Retrieved on: 
Sunday, December 10, 2023
ISIN, Depreciation, Ikon Office Solutions, Software, Software as a service, FUTURE, Growth, Acquisition, FP, EBITDA, EPS, ERP, Automation, Collection, Tax, DBS, CFO, Financial Oversight and Management Board for Puerto Rico v. Aurelius Investment, LLC, Round Table-class landing ship logistics, EBIT, EUR, Bookkeeping, Video game, Lithium

Berlin, November 23, 2023 –Francotyp-Postalia Holding AG (ISIN DE000FPH9000) today announced its financial results for the first nine months of 2023.

Key Points: 
  • Berlin, November 23, 2023 –Francotyp-Postalia Holding AG (ISIN DE000FPH9000) today announced its financial results for the first nine months of 2023.
  • Revenue of EUR 182.5 million declined by 3.3% compared to EUR 188.7 million in the same period of the previous year.
  • EBITDA for the first nine months of 2023 includes release of provisions of EUR 2 million due to changes in restructuring plans.
  • Free cash flow totaled EUR 5.6 million in the reporting period compared to EUR 6.9 million in the same period of the previous year.

Orkes Brings Generative AI and Human-in-the-Loop Capabilities to Microservices and Workflow Orchestration

Retrieved on: 
Wednesday, November 8, 2023
Internet, Data Management, Technology, Artificial Intelligence, Software, Cloud, Integration, Task, Foxtel, Create, Human, ChatGPT, Organization, LLM, Workflow, Ork (video game), Netflix, Safety, AI, Collection, DBS, OpenAI, Conifer cone, Logic, Video game, Customer service, Medical device

Orkes , the enterprise microservices and workflow orchestration platform for Netflix Conductor used by companies like United Wholesale Insurance, Foxtel, and Normalyze, has released new capabilities that allow organizations to implement generative AI models and vector databases directly into their microservices infrastructure and business workflows.

Key Points: 
  • Orkes , the enterprise microservices and workflow orchestration platform for Netflix Conductor used by companies like United Wholesale Insurance, Foxtel, and Normalyze, has released new capabilities that allow organizations to implement generative AI models and vector databases directly into their microservices infrastructure and business workflows.
  • “The biggest hurdle for our customers using generative AI technologies has been bridging the gap between having Gen-AI models and using them for actual enterprise-grade business workflows,” said Viren Baraiya , CTO at Orkes.
  • “We built Orkes AI Orchestration to provide enterprises an easy way for model inferences and vector DB tasks to be weaved into their business logic.
  • Orkes AI Orchestration and Human Tasks can be added to any of the Conductor clusters created and managed in Orkes Cloud.

Surgical Information Sciences Initiates VISION Study to Support Deep Brain Stimulation for Parkinson's Disease Patients

Retrieved on: 
Thursday, November 2, 2023
DBS, Physician, SIS, Deep brain stimulation, Research, GPI, STN, Surgeon, Subthalamic nucleus, Globus pallidus, Parkinson's disease, Hartford Hospital, Medical imaging, Patient, Disease

EDINA, Minn., Nov. 2, 2023 /PRNewswire/ -- Surgical Information Sciences, a medical device company focused on improved visualization of brain structures for deep brain stimulation (DBS) surgery, announced the commencement of its post-market study, the Visualization of the STN and GPi for DBS Surgery in Patients with Parkinson's Disease (VISION Study).

Key Points: 
  • EDINA, Minn., Nov. 2, 2023 /PRNewswire/ -- Surgical Information Sciences, a medical device company focused on improved visualization of brain structures for deep brain stimulation (DBS) surgery, announced the commencement of its post-market study, the Visualization of the STN and GPi for DBS Surgery in Patients with Parkinson's Disease (VISION Study).
  • This study aims to evaluate the potential of SIS technology in enhancing the accuracy of DBS implant placement for patients battling Parkinson's Disease.
  • The VISION Study will involve the participation of 90 patients across multiple sites, and it represents a significant step in the pursuit of improved treatment for those living with this challenging condition.
  • Dr. Patrick Senatus, a neurosurgeon at Hartford Hospital in Hartford, CT, commented, "The VISION Study presents an opportunity to assist surgeons and programming physicians in treating patients with Parkinson's Disease.

Procede Software Adds Key Functionality to Comprehensive Set of PACCAR Integrations with Three New Releases

Retrieved on: 
Tuesday, October 31, 2023
OEM, Kettler, E-commerce, DBS, Pearson, Filatima procedes, Original equipment manufacturer, Product management, Learning, Excede, Peterbilt, Ecosystem, SAN, Sales, PACCAR

SAN DIEGO, Oct. 31, 2023 /PRNewswire/ -- Procede Software, a leading heavy-duty commercial vehicle dealer business system (DBS) and solutions provider, today announced the release of three new integrations between its Excede software platform and PACCAR's proprietary systems. Together with Procede's existing PACCAR-specific integrations, they build on an already comprehensive integration set designed to streamline operations for dealerships across North America. The addition of these new integrations reflects Procede's ongoing commitment to building healthy relationships with OEMs across the industry for the benefit of its dealership network.

Key Points: 
  • Together with Procede's existing PACCAR-specific integrations, they build on an already comprehensive integration set designed to streamline operations for dealerships across North America.
  • Kettler continued, "A key part of that strategy is dedicating strategic resources to proactively build best-in-class OEM integrations.
  • Procede's comprehensive set of integrations between Excede and PACCAR's proprietary systems supports critical processes and operations for key departments across the dealership.
  • Procede engages closely with both OEMs and customers to identify key product development and integration opportunities to maximize business impact.

Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress

Retrieved on: 
Wednesday, October 25, 2023
Bone pain, Research, Plasma, Clinical trial, AAV, DBS, Biomarker, AST, Congress, Liver, Cancer Treatment Centers of America, CEST, Cell, Enzyme replacement therapy, White blood cell, Tissue, Gene, Glucocerebrosidase, Blood, ESGCT, Gaucher's disease, Safety, European Society for Primary Immunodeficiencies, Lysosome, ALT, Pharmaceutical industry, Patient

LONDON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate for Gaucher disease, show a substantial reduction of glucosylsphingosine (lyso-Gb1) levels in the blood of the first patient treated with FLT201. Lyso-Gb1 is a well-established biomarker of clinical response in Gaucher disease, with reductions in lyso-Gb1 correlating with positive clinical outcomes. These data are being highlighted in an oral presentation at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress held in Brussels, Belgium.

Key Points: 
  • Lyso-Gb1 is a well-established biomarker of clinical response in Gaucher disease, with reductions in lyso-Gb1 correlating with positive clinical outcomes.
  • These data are being highlighted in an oral presentation at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress held in Brussels, Belgium.
  • Reduction in lyso-Gb1 in the blood is strongly correlated with improvement in clinical outcomes in Gaucher disease.
  • The presentation entitled “Results from GALILEO-1, a First-In-Human Clinical Trial of FLT201 Gene Therapy in Patients with Gaucher Disease Type 1” is part of a session taking place from 14:30-16:30 CEST (8:30-10:30 a.m.